Clinical Trial

A Study of SKB107 in Advanced Solid Tumors With Bone Metastases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of SKB107 in subjects with advanced solid tumors with bone metastases.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-23; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2025-08-29
Trial Details
NCT Number NCT07087197
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Metastatic Solid Tumors
Enrollment 90 participants
Start Date 2025-08-15
Primary Completion 2027-10-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-08